FDA Approves Nucala for COPD Patients with High Eosinophil Levels
The U.S. Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as an add-on treatment for adults with chronic obstructive pulmonary disease (COPD) who continue to have flare-ups despite using triple inhaled therapy. Nucala is the first biologic drug specifically approved for COPD patients with an “eosinophilic phenotype”—a group defined by having high levels of
